Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an update.
MicroPort CardioFlow Medtech Corporation announced the formal release of one-year follow-up data from an early feasibility study of AltaValve, a transcatheter mitral valve replacement device independently developed by its associated company 4C Medical Technologies. The multicenter study in Europe, the U.S. and Japan enrolled 30 high‑surgical‑risk patients with severe symptomatic mitral regurgitation and showed a 97% technical success rate, complete elimination of regurgitation, improved hemodynamics, no cardiogenic deaths, and no major adverse events such as stroke or reintervention, with 96% of patients improving to NYHA Class I or II at one year. AltaValve, the world’s first atrial‑anchored, fully retrievable, low‑profile transseptal TMVR system, has received two FDA Breakthrough Device designations in 2024 and is in pivotal trials in Europe and the U.S., supported by a recent US$175 million Series D financing at 4C Medical. The results and regulatory momentum underscore the potential of AltaValve to strengthen MicroPort CardioFlow’s positioning in the global structural heart market, especially in its exclusive Greater China territories, while the company cautions that ultimate commercialization is not guaranteed.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a cardiovascular medical device company focused on structural heart disease, with a particular emphasis on transcatheter valve therapies. Through its associated company 4C Medical Technologies, it is involved in developing innovative devices for treating mitral and tricuspid regurgitation, and holds exclusive commercial rights for the AltaValve transcatheter mitral valve replacement system in Mainland China, Hong Kong, Macau and Taiwan.
Average Trading Volume: 4,607,838
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.3B
Find detailed analytics on 2160 stock on TipRanks’ Stock Analysis page.